| 前收市價 | 26.70 |
| 開市 | 27.34 |
| 買盤 | 27.02 x 500 |
| 賣出價 | 27.09 x 1000 |
| 今日波幅 | 26.61 - 27.82 |
| 52 週波幅 | 21.62 - 44.32 |
| 成交量 | |
| 平均成交量 | 1,918,396 |
| 市值 | 5.062B |
| Beta 值 (5 年，每月) | 1.06 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.23 |
| 業績公佈日 | 2024年8月01日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 49.75 |
Insider MonkeyBridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy Under $50. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other healthcare stocks under $50. If interested, you can also read our recent article on the 10 Best Healthcare Stocks To […]
InvestorPlaceThe 3 Best Biotech Stocks to Buy in June 2024
The biotech sector, under the life sciences umbrella, exited 2023 with 41 bankruptcies. This was not surprising given the disparity between biotech’s high-capital requirements and rising interest rates set by the Fed. Despite these challenges, some of the best biotech stocks show promise and resilience in a volatile market environment. At the same time, smaller biotech deals became prevalent, accounting for $17 billion during 2023, per JP Morgan data. Another noticeable trend was the uptick in m
Investor's Business DailyBridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug
BridgeBio stock gave up gains midday Tuesday after releasing a Phase 2 study on a growth disorder treatment.
